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A B S T R A C T
Estrogens and their bioactive metabolites play key roles in regulating diverse processes in health and disease. In
particular, estrogens and estrogenic metabolites have shown both protective and non-protective effects on disease
pathobiology, implicating the importance of this steroid pathway in disease diagnostics and monitoring. All estrogens
circulate in a wide range of concentrations, which in some patient cohorts can be extremely low. However, elevated
levels of estradiol are reported in disease. For example, in pulmonary arterial hypertension (PAH) elevated levels
have been reported in men and postmenopausal women. Conventional immunoassay techniques have come under
scrutiny, with their selectivity, accuracy and precision coming into question. Analytical methodologies such as gas
and liquid chromatography coupled to single and tandem mass spectrometric approaches (GC–MS, GC–MS/MS,
LC–MS and LC–MS/MS) have been developed to quantify endogenous estrogens and in some cases their bioactive
metabolites in biological fluids such as urine, serum, plasma and saliva. Liquid-liquid or solid-phase extraction ap-
proaches are favoured with derivatization remaining a necessity for detection in lower volumes of sample. The limits
of quantitation of individual assays vary but are commonly in the range of 0.5–5 pg/mL for estrone and estradiol,
with limits for their bioactive metabolites being higher. This review provides an overview of current approaches for
measurement of unconjugated estrogens in biological matrices by MS, highlighting the advances in this field and the
challenges remaining for routine use in the clinical and research environment.
1. Introduction
1.1. Estrogen biochemistry
Estrone (E1) and estradiol (E2) are the predominant circulating fe-
male sex steroids with multiple functions throughout the body. The
third most common form in humans, estriol (E3 or 16OHE2), can be
produced from estradiol or from estrone, the latter via the 16-hydro-
xyestrone (16OHE1) intermediate [1]. Estrogens can be synthesized on
demand in some tissues from the major circulating adrenal steroids
dehydroepiandrosterone (DHEA), andostenediol (A5), through andros-
tenedione (A4) and testosterone (T) [2] via the enzyme aromatase,
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Fig. 1. Ovaries are the main production site of estrogens in pre-
menopausal women, whereas tissues such as adipose play a greater role
post-menopausally [3]. Estradiol is the most abundant hormone in pre-
menopausal women, whereas estrone is more prevalent in post-meno-
pausal women and also in males, being generated from adrenal an-
drostenedione. Isomers of estradiol exist in α and β configurations; 17β-
estradiol (E2) refers to the main bioactive version whilst 17α-estradiol
is generally thought to be less active [4]. Estriol increases throughout
pregnancy being generated in the placenta. Aromatic oxidation of es-
trone and estradiol generates hydroxy-metabolites which are converted
to methoxylated metabolites, but the exact circulating level of each
remains largely unknown and under-investigated [5]. The levels of the
bioactive metabolites are assumed lower than the main circulating es-
trogens, Table 1.
Throughout this review all estrogens and metabolites will be re-
ferred to collectively as estrogens. Estrone and estradiol are in equili-
brium by interconversion by 17βHSD1 and 17βHSD2 enzymes, cata-
lyzing reduction or oxidation respectively at the C17 position ketone/
hydroxyl, and the balance largely favours estrone formation, Fig. 1.
Further metabolism occurs via cytochrome P450 (CYP) enzymes, gen-
erating bioactive hydroxy metabolites upon oxidation of the parent
molecules at the C16, C4 and C2 positions listed in the order of reactive
preference [6]. In the C16 position, oxidation can occur via CYP1B1 [7]
and 16OHE1 formed can be interconverted with 16OHE2. Both 16-
hydroxy estrogens are further metabolised by conjugation. The 2- and
4-hydroxy-estrone and estradiol metabolites, collectively known as
catechol estrogens (2OHE1, 4OHE1, 2OHE2 & 4OHE2), are rapidly
converted (t 1/2= 90min [8]) to 2- and 4-methoxy–estrone and es-
tradiol metabolites (2MeOE1, 4MeOE1, 2MeOE2 and 4MeOE2) by the
action of catechol-O-methyltransferase (COMT). Hydroxy and methoxy-
estrone and estradiol metabolites are also maintained in constant
equilibrium by 17βHSD1 and 17βHSD2 enzymes prior to their re-
spective metabolism and removal from the body mainly in the liver.
Estrogens are converted to glucoronide and sulfate conjugates and ca-
techol metabolites also form glutathione conjugates, all potential me-
chanisms of detoxification in hepatic and extra-hepatic sites [9].
1.2. Influence of estrogens in disease pathobiology
Epidemiological and experimental studies implicate estrogens in a
number of diseases with the potential roles of bioactive metabolites
becoming more prominent. For example, in cancer and cardiovascular
fields estradiol, 16OHE1, 2OHE2 and 4OHE2 have been implicated in
disease progression and 2OHE1, 4OHE1, 4MeOE1, 2MeOE2 and
4MeOE2 have shown protective roles. The remaining 2MeOE1 is
thought to be inactive [5,10]. At site specific locations prior to removal,
estrogens and the bioactive metabolites may act through genomic sig-
nalling cascades via estrogen receptors (ER) or alternatively by rapid
non-genomic actions via G-protein coupled estrogen receptor 1 (GPER)
and may directly alter protein signalling [11].
Elevated estrogen levels in serum and plasma of women in parti-
cular have been associated with increased risk of breast [12,13], en-
dometrial [14,15] and ovarian cancers [16,17], whilst in males es-
trogen-androgen imbalance is thought significant in the development of
aggressive prostate cancers [18]. Emerging evidence implicates es-
trogen metabolism in the aetiology of diabetes [19], possibly explaining
why in breast cancer obesity has proven to be a major contributing risk
Fig. 1. Endogenous steroid hormone pathway; formation of endogenous estrogen from sex hormone substrates dehydroepiandrosterone (DHEA), andostenediol (A5),
androstenedione (A4) and testosterone (T). Oxidative metabolism of estrone (E1) and estradiol (E2) at C2, C4 and C16 positions by cytochrome P450 enzymes leads
to the generation of hydroxyestrogen metabolites (2OHE, 4OHE & 16OHE). The 2OHE and 4OHE metabolites are rapidly converted to the methoxyestrogens by
catechol-O-methyltransferases (COMT). E1 and E2 metabolites are maintained in equilibrium through the actions of 17β-hydroxysteroid dehydrogenase 1 & 2
enzymes. Dysregulation in the balance of these metabolic pathways can be both protective and non-protective, examples being in pathophysiology of pulmonary
arterial hypertension and cancer.
Table 1
Reference ranges of concentrations of estrogens in human plasma.
Group Age Estrone Estradiol Estriol
(Y) (pg/mL) (pg/mL) (pg/mL)
Female Children 0-15 ND - 200 ND - 40 ND
Premenopausal 18-55 17 - 200 15 - 350 <80
Pregnancy – > 187 188 - 7192 >2100
Postmenopausal > 55 7 - 40 <10 ND
Male Children 0-18 ND - 46 ND - 38 ND
Males > 18 10 - 60 10 - 40 < 70
Concentration guidelines from Mayo medical laboratories (https://www.
mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/84230 and
www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/81711
accessed 15/07/2019); Children< 18 Y; ND=Not detected; Y= years.
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factor [20]. Most literature addresses estradiol and estrone; the bioac-
tive estrogen metabolites remain less studied but are now gaining more
prominence in each field. For example higher 16-hydroxy estrogen
production has been linked to greater risk of diseases such as prostate
cancer and pulmonary arterial hypertension (PAH) [18].
In oncology, several factors link predisposition to metastasis to es-
trogen bioactivity. Clinically, three main scenarios are presented; in late
menopause when site specific estrogen production and metabolism
becomes more prominent; in hormone replacement therapy use where
metabolic dysfunction occurs via increased exogenous supply; and
thirdly in the presence of specific single nucleotide polymorphisms
(SNPs) in aromatase that result in increased circulating plasma estradiol
levels [12]. All scenarios lead to exacerbation of breast cancer symp-
toms [10]. Over and above changes in estrone and estradiol signalling,
changes in urinary estrogen metabolite levels have been reported in
mammary tumours with an emphasis on the 2/16-hydroxyestrogen
ratio [21]. Here, higher levels of 2-hydroxyestrogens compared to their
mitogenic counterparts, 16-hydroxyestrogens, are associated with de-
creased risk of tumour growth and disease progression [22]. Specific
bioactive metabolites are also linked to cardiovascular disease [23–25]
with striking similarities to oncology findings. In PAH, a disease un-
derpinned by gender differences, understanding the actions of estrogens
and their metabolites may be key in elucidating the cause for female
predominance. Research, in vitro and in vivo has linked 16OHE1 to
cellular proliferation and vascular remodelling, significant phenotypic
hallmarks of PAH [26–28]. 16OHE1 exhibits a higher binding affinity
and estrogenic potency than parent molecules at classical estrogen re-
ceptors [29], potentially activating the classical genomic signalling
cascade and playing a pathogenic role in the pulmonary circulation. In
this setting, increased levels in urine [30] also coincide with induction
of smooth muscle proliferation within the pulmonary arteries [27].
Alternatively, metabolites like 2MeOE2 have demonstrated protective
effects via disruption of HIF1α signalling, decreasing mitogenic pro-
liferative effects within lung fibroblasts in an apoptotic manner [31].
Interestingly a recent comprehensive study has further implicated ele-
vated estradiol levels in male patients with PAH, linking this to poorer
clinical outcomes [32]. Therefore, the potential consequences of es-
trogenic hormone imbalance within the body, at site-specific locations
in both females and males, prompt investigation of the diverse profile of
circulating estrogens with the aim of developing targeted therapeutic
modulators within this sex hormone pathway.
2. Quantification of estrogens
This review will discuss approaches for analysis of unconjugated
estrogens.
2.1. Immunoassays
Measurement of circulating estrogens in clinical diagnosis, research
and monitoring often involves enzyme linked immunoassays (ELISAs)
and radioimmunoassays (RIAs) [33,34] and has largely focussed on
estradiol and estrone. Mainly these techniques are chosen due to their
low cost and routine nature [35]. Both rely on the action of an antigen
(estrogen) binding to specific antibodies; for ELISA, the detection of this
interaction is accomplished via incubation with a substrate(s) known to
emit a measurable product; for RIA, radioactive scintillation counting is
applied. These methods can lack selectivity, being dependent on anti-
body characteristics, often exhibiting cross reactivity between different
estrogens of interest and other species. This problem is particularly
marked when measuring lower levels. High selectivity at low con-
centrations is a critical requirement for accurate analysis of estrone and
estradiol particularly in men and older women, and the same rigour is
needed to assay low levels of bioactive estrogen metabolites [36,37].
Several studies for more abundant steroidal compounds such as cortisol,
testosterone and vitamin D illustrate an imprecision between reported
concentrations and a bias for false positives using immunoassays over a
number of analytical methods [38–40]; this has led to the Endocrine
Society issuing a consensus statement recommending avoidance of
immunoassays for steroid hormone assays [41]. Therefore, develop-
ment of robust analytical techniques capable of simultaneous quanti-
fication of panels of estrogens at low circulating concentrations be-
comes justified and here hyphenated mass spectrometry techniques
have led the way.
2.2. Analytical approach
The journey of estrogen quantification began with researchers ex-
ploring a wide variety of diverse matrices using high performance li-
quid chromatography (HPLC), with a few publications reporting
quantification of pharmaceutical estrogens within bio-fluids [42].
Transfer of methods for analysis of endogenous steroids by HPLC has
proven difficult, due to insufficient sensitivity. The majority of analy-
tical technologies that became available for clinical analysis of estro-
gens originally employed gas chromatography mass spectrometry
(GC–MS). In more recent years, with the evolution of narrower bore
liquid chromatography columns with smaller particle sizes, liquid
chromatography tandem mass spectrometry (LC–MS/MS) has increas-
ingly featured. Both approaches benefit from the use of stable isotope
internal standards (IS) and have levels of specificity unrivalled by
ELISAs and RIAs. Initially attempts to transfer to MS approaches were
hampered due to sensitivity issues which can now be overcome by
newer instrumentation, [34,43,44], and a number of successful ap-
proaches have now been published (Tables 2 and 3 and Fig. 2). Only a
few of these methods include the bioactive metabolites. The critical and
defining factors underpinning improvements in speed, sensitivity and
reliability are tabulated and discussed below.
2.3. Methods of detection and quantitation
Mass spectrometers interfaced with GC and LC have both been
successfully applied to analyse estrogens in plasma and/or serum, with
a number of validated methods reported, Table 2, following the general
principles in Fig. 2. It is important to recognize that when studying a
family of related molecules that several estrogens may fragment to the
same ion, and efficient chromatographic separation remains essential to
avoid isobaric interferences. This happens for example between isomers
and isotopologues, notably [M+2], being a particular problem with
groups of molecules interconverted between ketones and alcohols by
oxidation/reduction. These possibilities must be planned for and thus
potential sources of interference excluded upon method validation. For
MS, single quadrupoles were initially developed allowing one mass
filter to be applied for selection of a single m/z ratio in an approach
known as selected ion monitoring (SIM). Advances in this technology
led to the introduction of triple quadrupoles, allowing double mass
filtering of initial precursor ions and their breakdown fragments (pro-
duct ions) – known as multiple reaction mode (MRM). Triple quadru-
pole MS operated in MRM rather than conventional SIM provide a much
higher selectivity, with less interference from co-eluting matrix com-
ponents and thus increased signal to noise ratio. This has allowed en-
hanced selectivity over wide dynamic ranges and improved accuracy
and precision of assays. Quantitation with high resolution or accurate
mass analysers is possible but still in its infancy, held back in some cases
by poorer quantitative performance due to narrower dynamic ranges
[64]. Quantitative performance of these diverse analysers is variable,
with Time-of-Flight instruments to date performing less well (Table 3)
but some valuable methods coming forward with Orbitrap® technology
[30,63]. Their value in the field for structural identification and elu-
cidation of fragmentation is however extremely important and well
established [70,77].
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2.4. GC–MS (/MS)
In GC, the mobile phase is an inert gas (usually helium) and the
stationary phase is a viscous liquid that coats the walls of the capillary
column. Analytes must vaporize and then dissolve into the stationary
phase upon injection onto the GC column. Subsequently they are vo-
latilized, and efficient phase transfer of steroids usually requires che-
mical derivatization. The derivatized steroids are resolved on the ca-
pillary column based on their relative affinities for the stationary phase
and the temperature gradient applied to the GC oven. Stationary phases
with phenyl groups have been most commonly used for estrogen ana-
lysis, as П- П interactions with the phenolic A-ring enables resolution of
more challenging mixtures. Historically and still today greater resolving
power is afforded with GC than LC, an important factor for improving
isomer resolution and accurate and specific quantification.
Chemical derivatization is applied with a range of reagents reported
in Table 2. For MS analysis, both electron impact (EI) and chemical
ionization (CI) have been used and of these, CI in conjunction with
tandem MS is favoured in the literature. This is due to improved sen-
sitivity brought about by electron capturing halogenated derivatization
reagents. Accordingly the vast majority of GC–MS/MS approaches
capable of detection of estrogens at low concentrations employ negative
ion mode, although positive ionization has been employed in con-
junction with ion-trap technology successfully achieving a lower limit
of quantitation (LOQ) of 13–21 pg/mL [45]. However, this would not
be sufficiently low for certain patient cohorts, Table 1. Urinary analysis
of estrogens and their bioactive metabolites by GC typically involves
extended sample preparation (two-step extraction) [48]. For analysis of
estrone and estradiol in serum, these types of extractions in conjunction
with derivatization show reliable detection, however extensive sample
preparation can be required, for example with both liquid-liquid ex-
traction (LLE) and solid phase extraction (SPE) for estrone and estra-
diol, to allow detection at 0.5 pg/mL in 250 μL of rodent serum [46].
Approaches using SPE are most efficient for single step methods, with
applications reporting limits of 1.9 pg/mL from 1mL of serum from
post-menopausal women [37] and 2.5 pg/mL in an application note
from 1mL serum [47]. Notably methods have not been reported for
catechol and hydroxyl metabolites of estrogens in plasma by GC, al-
though in principle this should be achievable as they have been
detected in urinary samples [48]. Although GC–MS/MS inherently al-
lows enhanced chromatographic resolution vs LC-MS(/MS), its routine
application suffers from time consuming runs (30min – 1 h), extensive
sample preparation, use of high temperatures that may be detrimental
to thermo-labile compounds and complex fragmentation of precursor
ions within the MS source. LOQs for a subset GC methods remain
marginally outside the clinical range, with only one study in range
reaching an LOQ of 0.5 pg/mL. This approach has still to be tested in
human serum as opposed to rodent and relies on extensive sample
preparation [46]. LC–MS(/MS), using softer ionization techniques, are
more likely to generate charged molecular ions. Thus, there has been
much interest in bringing LC–MS(/MS) methods to the fore. This may
provide higher throughput, although it is worth debating whether
adequate sensitivity can be achieved without derivatization.
2.5. LC–MS (/MS)
LC–MS/MS is fast becoming the favoured approach for steroid
analysis in clinical laboratories worldwide consequent to technological
advances in ion formation, transfer and detection. For the applications
discussed here, reversed phase chromatography is almost exclusively
used, using LC columns with hydrophobic stationary phase in con-
junction with a polar mobile phase. C18 columns
[49,55–57,61,63,64,69,70,72,78] with their enhanced retention cap-
abilities and robust, consistent manufacturing quality are preferred.
Chemical alterations to bonded stationary phases, again exploiting in-
teractions with the aromatic ring, can improve distinction of isomeric
structures, typically required for the estrogen metabolites. Efficiency of
separation can be enhanced by use of smaller particle sizes and longer
columns, parameters which are inversely proportional to chromato-
graphic efficiency [70]. Pairings of a wide variety of mobile and sta-
tionary phases are cited each with their own individual benefit. The
careful choice of gradient elution parameters improves robustness of
the assay, incorporating time for equilibration, elution and column
cleaning. While ballistic gradients are attractive in reducing analysis
times and in the cleaning phases, more subtle gradients are often ne-
cessary to resolve isomers. Normally combinations of either methanol
or acetonitrile and water are used [49,54,70] with only one report
using both acetonitrile and methanol [56].
Table 2
Estrogen (unconjugated) quantification by GC–MS(/MS).
Analyte Matrix Extraction
Type
V (mL) Derivatizati-
on Agent
Inj V
(μL)
Column MS Mode
(+/-)
LOQ (pg/
mL)
Ref
E1, E2 Serum LLE 1 TMSI 1 TR-50MS 50% phenyl polysilphenylene-siloxane
30m×0.25mm
(0.25 μm)
Ion Trap
EI-MS/MS
+ 13-21 [45]
E1, E2 Serum LLE & SPE 0.25 PFBHA
PFBO
NS DB-17HT, 50% phenylmethyl polysiloxane
15m×0.25mm
(0.15 μm)
Triple Quad
CI-MS/MS
– 0.5 [46]
E2 Serum SPE 1 PFBO
PFBHA
MSTFA
NS DB-17 fused silica
Dimensions NS
Triple Quad
CI-MS/MS
– 1.9 [37]
E2 Plasma SPE 1 PFBC
MSTFA
1 50% phenyl-methylpolysiloxane phase
15m×0.25mm
(0.25 μm)
Triple Quad
CI-MS/MS
– 2.5 [47]
E1, E2, 16OHE,
16EpiOHE2,
16KetoOHE2,
17EpiOHE2,
2,4OHE, 2OHE-
3ME, 2,4MeOE
Urine SPE 2 EOC
PFP
2 MXT-1, Silcosteel-treated stainless steel
30m×0.25mm
(0.25 μm)
Single Quad
EI-MS
+ 20-500 [48]
Chemical Ionization (CI); estrone (E1); estradiol (E2); ethoxycarbonlyation (EOC); Gas Chromatography (GC); 2, 4, 16-hydroxyestradiol (2, 4, 16-OHE2); 2, 4, 16-
hydroxyestrone (2, 4, 16-OHE1); 2-hydroxyestrone-3-methyl ether (2OHE-3ME); 16β-Hydroxy-17β-estradiol (16epiOHE2); 16-oxo-17β-estradiol (16ketoOHE2);
16α-hydroxy-17α-estradiol (17epiOHE2); 17α-estradiol (17epiestradiol); Liquid Liquid Extraction (LLE); methoxyestrogens (MeOE); N-methyl pyridinium-3-sulfonyl
N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA); Not stated (NS); pentadecafluorooctanoyl chloride (PDFO); pentaflurobenzoyl hydroxylamine hydro-
chloride (PFBHA); perfluorobenzoyl chloride (PFBO); Solid phase extraction (SPE); Tandem mass spectrometry (MS/MS); N-(trimethylsilyl)imidazole (TMSI).
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Given the low abundance of estrogens, it is unsurprising to see the
use of triple quadrupole instruments, with their improved signal to
noise, dominating over that of single quadrupole systems (Table 3).
Positive-mode electrospray ionization (ESI) analyses are most promi-
nent, at least for derivatized samples, Table 3, but alternative soft io-
nization modes are also reported, namely atmospheric pressure che-
mical ionization (APCI), and the more recent atmospheric pressure
photoionization (APPI) [49,79]. Estrogen analyses are reported in both
positive and negative ionization modes dependent on the charge due to
(de)protonation or coupled by derivatization. Mobile phase modifiers
such as formic acid, ammonium formate or acetic acid are frequently
added.
Limits of quantitation by LC–MS/MS are reported over a wide range
of 0.14–3000 pg/mL for estrone and estradiol. Inclusion of metabolites
to create assay panels might be associated with a reduction in sensi-
tivity due to lower dwell times for each scan but this is not that ap-
parent in the applications reported in Table 3. Generally, 0.1–2mL of
serum or plasma are required although 0.5mL or below is desired for
routine collection without excessive blood loss. The limits and volumes
differ somewhat between ionization methods, Table 3. Examples in-
clude low limits of detection (0.5–2.4 pg/mL) for metabolite panels in a
study of breast cancer patients [65], and again in another study of
pulmonary hypertensive patients (2–10 pg/mL) [70]. Negative mode is
more commonly used in non-derivatized samples [36,51], capitalizing
on the presence of a phenol within the estrogen structure with methods
generally reporting limits of ∼1 pg/mL for estrone and estradiol.
However ionization of non-derivatized estrogens in ESI mode occurs
within charged droplets in competition with alternative species present
Fig. 2. Schematic workflow for analysis of estrogens by mass spectrometry.
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in endogenous mixtures, which can cause ion suppression and this
parameter must be evaluated in method development [80]. As an al-
ternative, APCI is less liable to ion suppression as is APPI, the latter
using photons from a discharge lamp to aid ionization of molecules.
Reported applications of APCI methodologies for estradiol analysis
have low limits of 0.5 pg/mL in serum [49] and 1 pg/mL in saliva [66]
with limits for APPI reported as 3–5 pg/mL for estrone, estradiol and
estriol in mouse serum [51]. Rahkonen et al presented a comprehensive
comparison of all ionization modes and polarity combinations for es-
tradiol analysis clearly demonstrating APPI in negative mode to have
the lowest LOQ at 0.14 pg/mL. Using this approach, low concentrations
in pooled serum were detected using ammonium hydroxide as an ad-
ditive, Table 3 [49]. Upon application to a clinical cohort (200 μL), a
DMIS derivatization approach in conjunction with APPI was applied by
the same group reporting limits in serum of 0.5 pg/mL [50]. Notably
addition of 2D chromatography boosts sensitivity for estrone and es-
tradiol reducing LOQs tenfold [53] and integration of this with APPI
might allow a further boost in quantification capabilities. As of yet APPI
is not widely reported or available and, although advantages of APCI/
APPI over ESI exist, the majority of routine analytical assays applied in
clinical laboratories use ESI, creating a deterrent to regular exchange
between MS interfaces and hindering their extended application.
Alternative LC approaches such as ultra-flow LC (UFLC-MS) might
be applied allowing reduction of flow rates (1–100 μL/min) combined
with columns of smaller dimensions (ID; 0.1 and 1.0mm). Advantages
suggested include the ability to use smaller volumes of solvents which is
of economic and environmental benefit, wider dynamic ranges and
improved sensitivity [81]. A further application of microflow was in-
troduced as the Ion Key® source from Waters, allowing direct infusion
of microflow-LC into the MS with reported advantages of improved
sensitivity, chromatographic performance and importantly robustness.
This has been exemplified in a technical report for estrone, estradiol
and estriol, with LOQs for non-derivatized steroids of 1 pg/mL, using
negative-ESI with ammonium hydroxide as a mobile phase modifier for
deprotonation. The authors here suggest clear analytical advantages
over non-derivatized methods by conventional ESI-LC–MS/MS methods
[81] but this is not always the case as shown in Table 3. In another
study by Wang et al using nano-LC technology for analysis of serum in
men, LOQs reached 0.5 pg/mL for estradiol and its metabolites except
in the case of catechol estrogens whose limits were 5 pg/mL [61].
However, again this approach is not yet in routine use. Overall, a wider
application of LC–MS/MS than GC–MS/MS for quantification of es-
trogen and its bioactive metabolites in plasma, serum and more recently
in saliva has been demonstrated.
2.6. Future perspectives on analytical technology
Simultaneous analysis of estrogen metabolite panels in biological
matrices constitutes a difficult task. This subgroup of steroids, with
their low abundance, has created and still presents challenges for
analysts in the search for high-throughput, facile and sensitive assays.
With the advances in technology, this is now within grasp, but to
quantify these molecules the sample volumes required are still rela-
tively large and considerably more than for other steroids such as an-
drogens. In the future, aside from advances in standard GC or LC triple
quadrupole technology, coupling of MS/MS to advanced chromato-
graphic technologies such as supercritical fluid chromatography, ion
mobility MS and micro-LC/nanospray might permit improved sensi-
tivity and shorter run times. Proponents of supercritical fluid chroma-
tography suggest that this separation method harnesses the advantages
of both LC and GC, commonly employing methanol/carbon dioxide
linear gradients as a mobile phase and resulting in faster separations
and higher efficiencies than conventional GC. This non-polar solvent
system has a low backpressure, allowing higher flow rates than LC due
to the viscosity of the mobile phase being more similar to gas rather
than liquid. Application to a panel of 15 estrogen metabolites in urine
and serum was trialled for estrone, estradiol, estriol, 16-hydroxy, 16-
ketohydroxy, 2-hydroxy, 4-hydroxy, 2-methoxy and 4-methoxy–estro-
gens showing fast run times and 5 pg quantification limits [82]. This has
yet to be validated for routine use and the availability of in-
strumentation is still restricted. Ion mobility mass spectrometry (IMS)
provides an interface between the LC and MS/MS systems allowing
separation of ions in the gas phase. Discrimination is based on their
mobility differences in either high vs low electric fields and is depen-
dent on their collisional cross sections. There are three main forms of
IMS, drift tube (DT-IMS), travelling wave (TW-IMS) and field asym-
metric/differential (FA/D-IMS). Of these, DIMS has been applied suc-
cessfully to tissue samples for separation of estrone, estradiol and estriol
from American eels [83]. In this case, ion mobility allowed efficient
separation of structural isomers whilst reducing background noise over
conventional ionization methods. For quantitation, IMS in principle
may allow better signal to noise within the detector since species
creating contemporary noise maybe separated from analytes through
differential mobility. Isomeric estrogens have extremely similar mobi-
lity but the potential exists for derivatization to exaggerate structural
difference and subsequently increasing separation between structural
isomers [84]. As of yet this approach has not been commonly em-
ployed, perhaps due to a lack of dedicated systems in academic la-
boratories.
2.7. Sample preparation
Prior to quantification estrogens must be efficiently extracted from
the matrix of choice. In the case of LC–MS/MS analysis, ion suppression
arises due to sample components, such as phospholipid and salt inter-
ference. Phospholipids remain the number one cause of diminished
signal responses for analytical applications by LC–MS/MS. GC, how-
ever, does not suffer from this phenomenon due to the high energy
nature of its ionization source, although remaining matrix components
can cause undesirable deposits in the injector, start of the column or in
the source and will lead reduced sensitivity and poor peak shapes. For
either approach, sufficient removal of interfering compounds and
lowering of background noise by sample pre-treatment is of paramount
importance when approaching estrogen assay development.
2.7.1. Liquid-liquid extraction (LLE)
LLE provides an inexpensive approach to extract estrogens from the
sample matrix exploiting their relative solubility in organic solvents.
LLE has been used extensively and as a result is most common for the
analysis of estrone and estradiol in serum [35,59]. Ultimate recovery
and suppression of LLE approaches are dependent on the choice of
extraction solvent. Solvents for extraction of estrogens into the organic
phase include methyl tert-butyl ether (MTBE), ethyl acetate, diethyl
ether, dichloromethane or mixtures of these organic solvents. Ethyl
acetate is most commonly reported affording high recoveries [85,86]
and alongside MTBE, it yields a clean extract that avoids precipitation
upon derivatization [87,88]. From Table 3, it can be seen LLE has been
extensively applied to estrone and estradiol assays reporting low de-
tection limits (0.14–5 pg/mL). However, for bioactive metabolites re-
sults are variable with higher limits than alternative sample preparation
techniques (5–360 pg/mL). Additional drawbacks of LLE for routine
testing also relate to its manual nature, commonly being more time-
consuming and potentially exposing the analyst to high volumes of
organic solvents. Sample loss through transfer between test tubes and
plastic plates has been noted using LLE possibly contributing to inter-
day imprecision [49].
2.7.2. Solid phase extraction (SPE)
Off-line SPE is an attractive alternative to LLE. It is often employed
for analysis of estrogens in water (i.e. for processing larger sample
volumes), but also with effective application in the clinical setting in
saliva, serum and plasma [54,68,72]. SPE extraction cartridges come
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embedded with a range of solid packing materials, which chemically
separate the components of interest from the biological samples. Vari-
eties of bed are commercially available containing reversed, normal,
ion exchange or adsorption packing materials. For recovery of estrogens
from aqueous sample matrices, reversed and ion exchange phases are
recommended and are reported to be effective for clean up of plasma
samples, Table 3. In principle, an SPE column containing an alternative
packing material to the chromatography column holds advantages in
improving sample clean up. SPE columns used for estrogen analysis
often have C18 beds, but many commercial materials also exist such as
Oasis HLB®; most have hydrophobic characteristics optimal for inter-
actions with the lipophilic features of steroid hormones. HLB® operates
over a wide range of pH values suitable for many compound classes.
Choice of SPE column is based on achieving high recovery with low ion
suppression, which can be difficult to achieve with complex matrices
such as plasma [71]. A study by Faqehi et al 2016 suggested the use of
Oasis MCX®, a cartridge housing a mixed mode cation exchange reverse
phase bed, provides opportunities for additional sample clean up prior
to the elution of the estrogen and this has been shown effective for a
panel of the bioactive estrogens, including metabolites upon optimi-
zation of wash steps [70]. Other groups suggest the use of C8 poly-
propylene columns conditioned and cleaned with 0.1% TFA improved
recovery and diminished ion suppression for a panel of 10 estrogens
[65]. Moving forward with SPE, newer products eliminate the need for
conditioning and equilibration steps and availability of 96-well plates
allow potential automation for robotic liquid handling systems. The
main disadvantage with SPE for routine clinical analyses associates
with the cost, as cartridges remain expensive. Moreover, coupling SPE
and derivatization can introduce undesirable transfer steps and also
losses depending on the type of collection container required to avoid
adhesion (glass vs plastic). Glass inserts for 96-well plates are expensive
and only available for lower elution volumes. On-line SPE methods are
available although less frequently reported as they can be complicated
to develop without compromising the analytical chromatographic step
[89]. However once the elution programme is optimized, directly
linking the extraction processes to LC–MS/MS can improve recovery
and sensitivity and minimize manual sample manipulation [90].
2.7.3. Supported liquid extraction (SLE)
Supported liquid extraction (SLE) opens doors to new approaches
for extraction but as yet methods for estrogen analysis have been
scarcely published, unlike with other steroids [91]. This strategy shows
promise in company application notes [92] with successful application
to androgen profiling for diseases such as congenital adrenal hyper-
plasia [93]. SLE applies the same solvent affinity principles as LLE
whereby analytes are separated based on their partitioning into one
solvent over another immiscible solvent and employs similar solvents.
The support material consists of diatomaceous earth, a natural silica
product (∼90% silica), being an ideal material to absorb aqueous
samples. This technique allows shorter load, wait and elute protocols to
the generic SPE approaches, and the conditioning and equilibration
steps of the cartridge bed are not needed. However, options for sample
clean-up are limited in comparison to SPE. Again, SLE can be fully
automated in 96-well formats but again there are challenges in inter-
facing with containers suitable for derivatization. One application for
analysis of estrone, estradiol or estriol from 100 μL of plasma in the SLE
96 well format shows potential with low limits of 1, 3 pg/mL for es-
trone, estradiol respectively and 30 pg/mL for estriol. This extraction
method should now be tested with the wider panel of metabolites on
more sensitive MS platforms.
2.7.4. Derivatization
Derivatization can be necessary prior to analysis of estrogens by MS,
but with different goals for GC and LC. In the case of GC it is necessary
to enhance volatility often with the introduction of halogen atoms, also
enhancing sensitivity of CI approaches [79]. For LC, derivatization is
often employed to aid formation of charged ions or generate perma-
nently charged species. This increases sensitivity, and the greater mass
of the molecular ion holds further benefits for specificity. In GC–MS/MS
the process sometimes adds poorly volatile reagents which cannot be
easily removed. In both GC and LC, derivatization reagents can build up
in the chromatographic column or within components of the mass
spectrometer, thus decreasing assay robustness. In LC, this may be ad-
dressed by diverting the initial flow prior to analyte elution to waste,
removing polar reagents and maintaining a clean interface and source
within the mass spectrometer. In GC frequent cleaning of the inlet liner
will be required.
2.7.4.1. GC approaches. In GC–MS/MS derivatization at the 3′ position
of the A-ring is favoured as reactions at the saturated aliphatic D ring
largely do not improve sensitivity over non-derivatized samples
illustrated by pentafluoropropionyl (PFP) or trimethylsilyl (TMS)
derivatives for water analysis by GC–MS/MS [94,95]. The generation
of PFB derivatives is the most commonly reported approach for estrone
and estradiol analysis in serum, but cumbersome sample preparation
steps have, however, hampered routine use [37,46,96].
2.7.4.2. LC approaches without derivatization. Development of
analytical workflows of sufficient sensitivity without derivatization
remains challenging for clinical applications of estrogen analysis,
although they are desirable with sample preparation being shorter
with a lower chance of introducing manual varation. Moreover,
automation of derivatization by commercial robots is challenging to
couple with robotic SPE/SLE workflows. However, a number of
methods for underivatized estrone and estradiol using LC–MS/MS are
beginning to surface, (Table 2) as instrument technology improves.
Methods achieving LOQs comparable with derivatization approaches
have been reported using ammonium fluoride or ammonium hydroxide
as mobile phase modifiers, promoting the formation of negative ions
[59,72]. Recent analyses of estradiol report low LOQs, for example of
2 pg/mL using an UHPLC System coupled to a Xevo TQ-S [73]. Methods
without derivatization are yet to be extended to include bioactive
estrogen metabolites. If optimized successfully, validation of such
assays would permit simplified sample preparation with the
possibility of higher precision and throughput.
2.7.4.3. LC approaches with derivatization. Derivatization remains
necessary for the majority of LC–MS assays of estrogens, overcoming
poor ionization, limiting ion suppression and boosting signal intensity
at low abundance. In reactions reported, introduction of easily
ionizable groups or pre-charged moieties improves sensitivity and
permits the use of lower volumes of sample. As in GC–MS, the
hydroxyl group of the phenolic A ring in the 3′ position is usually
targeted for the entire analyte panel. Successful derivatization methods
commonly reported for analysis of estrone and estradiol include use of
dansyl chloride [68,92,97,98], N-methyl-nicotinic acid N-
hydroxysuccinimide ester [64], 2-fluoro-1-methylpyridinium-p-toluene
sulfonate [71], methyl-1-(5-fluoro-2, 4-dinitrophenyl)-4,4-
dimethylpiperazine [56,70], isomers of 1,2-dimethylimidazole-
sulfonyl chloride [63,99], picolinoyl carboxylate [67], pyridine
carboxylates [100], pyridine-3-sulfonyl chloride [52] and p-
nitrobenzyl chloride [101]. From these, dansyl chloride has been the
most common approach. However, the specificity of the fragment ions
of dansyl chloride derivatives is hindered for isobaric estrogen
metabolite species since the product ions generated are identical,
hailing from the derivative [63,97,98]. This is similar for alternative
derivatives such as BMP [65], whereby methyl-propyphenazone
derivatives generate identical product ions for seven estrogens whilst
differing by m/z 15 for the catechol metabolites. This source of non-
specificity has been partially overcome by use of MPPZ and C1-NA-
NHS, yielding a range of product ions, but they remain identical for
certain groups of metabolites [64,70], since isomers undergo similar
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fragmentation patterns. Therefore, thorough evaluation of
chromatographic methods becomes a necessity, to eliminate possible
co-elutants that may be mis-identified leading to reporting of false
positives. It should not be forgotten that estradiol and estrone only
differ by 2 mass units so 13C2 isotopologues used as internal standards
will cross-signal if product ions are identical. It is not uncommon for
multiple aliphatic and phenolic hydroxyl groups to be derivatized
within the reaction especially within 16-hydroxy- and catechol
estrogens [56,102], yielding either doubly or triply charged species
or isomeric derivatives. Finally, if derivatization is deemed necessary
the stability of derivatives should be considered and must be studied to
ensure practical laboratory workflows e.g. FMP derivatives degrade
following 48 h at −20 °C but remain stable within −80 °C storage [71].
MPPZ derivatives show minimal degradation (< 15%) upon storage for
8 days in the autosampler and for up to 31 days in −20 °C storage [70].
Dansyl chloride derivatives have also been reported to be stable over a
7 day period in patient plasma [54]. However, in the majority of
current literature, this information is lacking for derivatization
approaches. Derivatization techniques are still less preferred in the
clinical setting, due to the addition of another complexity within
sample preparation inevitability contributing toward data variability
and increased turn-around time.
2.7.5. Internal standards
An important feature of MS analytical methods for estrogen quan-
tification is the availability of stable isotope labelled internal standards
(IS) giving a retention time match to both derivatized and non-deri-
vatized estrogens. Addition at constant concentrations within the assay
accounts for extraction loss at all stages. 13C-labels allow additional
selectivity over deuterium-labelled standards, since they are highly
unlikely to be removed during processing. Deuterium can be removed
through either deuterium-hydrogen exchange under acidic conditions
or, depending on the positions of the labels, during derivatization re-
actions. By GC and LC, the retention time of 13C-labelled standards are
well aligned whereas deuterated IS may differ slightly, probably due to
isotope effects on hydrogen vs deuterium bonding interactions with the
stationary phase. The slight differences in retention time that arise with
deuterium labels are exaggerated when the number of heavy labels is
increased potentially leading to less accurate quantitation with less
specific interpretation of matrix effect [103]. However deuterium la-
belled standards are applied in a number of studies generally being less
expensive in comparison to the 13C labelled versions [51,53,57,63,65].
Retention of the stable isotope labels in the product ion is desirable to
enhance specificity, but labels can be lost in fragmentation, leaving
product ions identical in m/z to the analyte. C3-6 labelled standards are
now available for all estrogens shown in Fig. 1. Multi-labelled stan-
dards, preferably in excess of two labels, e.g. 13C3 and 13C6. should be
utilized, to avoid interference with natural isotopologues [61,70].
3. Conclusion
As this review highlights, there is no universal method for estrogen
analysis, however the wide range of approaches developed over the
past 10–15 years allows us to nudge closer to the possibility of routine
investigation and monitoring of estrogen sensitive diseases. On com-
parison of technologies available, methods by GC–MS initially came to
the field and currently offer a range of LOQs between 0.5–21 pg/mL for
estrone and estradiol in serum, plasma and urine, with 20–500 pg/mL
for their metabolites. However, despite efficient resolution of isomers,
GC–MS(/MS) is less favoured requiring more extensive sample pre-
paration and the absolute requirement for derivatization limiting au-
tomation. Developments in LC–MS/MS arose more recently, with
technology still advancing, offering the possibility of lower detection
limits of 0.14 pg/mL for standalone estradiol analysis with a range more
commonly between 0.5–21 pg/mL for estrogens in panel assays.
Although UHPLC may reduce analysis times in conjunction with MS,
applications show similar limits of detection to conventional HPLC and
GC. SPE and SLE extraction methods will likely lead the way forward in
clinical assays due to the possibility of automation. Applications in-
volving derivatization are not universally superior with a number of
methods not requiring derivatization now emerging that display similar
or even lower detection capabilities. Therefore, development of ap-
proaches without this step should be considered on newer triple
quadrupole instrumentation. In this setting APCI and APPI modes have
yet to be explored for the full metabolite panels. Irrespective of ana-
lytical technology used, the importance chromatographic development
must not be understated due to estrogenic isomers, stereoisomers and
isobaric confounders. Combinations of on-line SPE, high-resolution LC
and MS approaches may shape the future for automated approaches;
ion mobility might also provide a key approach for separation of iso-
mers, enhancing structural confirmation in cases where shared product
ions arise.
In conclusion, advancing research into health and disease in clinical
cohorts extending to children, men, and pre/post-menopausal women
for disease diagnostics and monitoring means limits of analytical
methods are constantly being tested. MS has established its place at the
forefront of research for estrogen quantification in clinical laboratories,
with LC–MS/MS beginning to show potential for routine applications.
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